NextPoint Stock
HealthTechLooking to sell NextPoint stock or options?
NextPoint specializes in developing medications aimed at enhancing the effectiveness of immunotherapies for cancer patients. The company is focused on creating a comprehensive and strategic pipeline of pioneering immunotherapies, leveraging a novel and validated checkpoint axis. This approach enables healthcare professionals to broaden the scope and potential of immunotherapy treatments.
Investors Include:
Bluebird Bio, MPM BioImpact, Catalio Capital Management, Sanofi Ventures, Pagoda Tree Partner, Sixty Degree Capital, WTT Investment, Leaps by Bayer, Binney Street Capital, The Invus Group, Arkin Bio Ventures.